Topic: Advanced Research on Molecular Mechanisms of Cancer Drug Resistance
Guest Editor(s)
Special Issue Introduction
The tumor-resident microbiota has been linked to cancer drug resistance, and manipulation of this microbiota is a novel strategy for the prevention and treatment of cancer drug resistance. Some microbiota demonstrate antitumor activity, thereby improving the tumor microenvironment, activating immune cells including dendritic cells, helper T cells, natural killer cells, and cytotoxic T cells, and upregulating the secretion of pro-tumor immune cytokines such as interleukin-2 and interferon. Tumor-resident microbiota and specific metabolites play crucial roles in designing anticancer resistance drug and their targeted delivery.
Keywords
Tumor-resident microbiota, Immune checkpoint inhibitors, microbiota metabolites, anticancer drug design, drug targeted delivery
Submission Deadline
1 Oct 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR231230
Submission Deadline: 1 Oct 2024
Contacts: Fiona Zhao, Assistant Editor, Fiona@oaeservice.com
